Ignite Creation Date:
2026-03-26 @ 3:15 PM
Ignite Modification Date:
2026-03-30 @ 9:02 PM
Study NCT ID:
NCT07492550
Status:
NOT_YET_RECRUITING
Last Update Posted:
2026-03-25
First Post:
2026-03-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
The T1DWATCH Study: a Screening for Type 1 Diabetes Autoantibodies in Children for Early Detection and Intervention.
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2026-03-25'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003922', 'term': 'Diabetes Mellitus, Type 1'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}], 'ancestors': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2025-11-25', 'size': 567509, 'label': 'Informed Consent Form', 'hasIcf': True, 'hasSap': False, 'filename': 'ICF_000.pdf', 'typeAbbrev': 'ICF', 'uploadDate': '2026-03-16T06:46', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 2200}, 'targetDuration': '3 Years', 'patientRegistry': True}, 'statusModule': {'overallStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2026-05', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2026-03', 'completionDateStruct': {'date': '2027-12-30', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2026-03-19', 'studyFirstSubmitDate': '2026-03-16', 'studyFirstSubmitQcDate': '2026-03-19', 'lastUpdatePostDateStruct': {'date': '2026-03-25', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2026-03-25', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2027-12-30', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of detected cases', 'timeFrame': 'Baseline through study completion, an average of 2 years', 'description': 'Key outcomes include the number of detected cases, defined by the presence of at least one autoantibody or two confirmed Ab.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Diabetes TYPE 1', 'Children', 'Autoantibodies', 'Screening', 'Primary Health Care', 'Autoimmunity'], 'conditions': ['Diabete Type 1']}, 'referencesModule': {'references': [{'type': 'BACKGROUND', 'citation': 'https://salutpublica.gencat.cat/web/.content/minisite/aspcat/promocio_salut/infancia-adolescencia/02infancia-amb- salut/protocol-preventiu-edat-pediatrica-2025.pdf'}, {'pmid': '10725812', 'type': 'BACKGROUND', 'citation': 'Luger TA, Kalden D, Scholzen TE, Brzoska T. alpha-melanocyte-stimulating hormone as a mediator of tolerance induction. Pathobiology. 1999;67(5-6):318-21. doi: 10.1159/000028089.'}, {'pmid': '34740879', 'type': 'BACKGROUND', 'citation': 'Besser REJ, Ng SM, Gregory JW, Dayan CM, Randell T, Barrett T. General population screening for childhood type 1 diabetes: is it time for a UK strategy? Arch Dis Child. 2022 Sep;107(9):790-795. doi: 10.1136/archdischild-2021-321864. Epub 2021 Nov 5.'}, {'pmid': '9114719', 'type': 'BACKGROUND', 'citation': 'Brady RC. Index of suspicion. Case 2. Diagnosis: gonorrhea conjunctivitis. Pediatr Rev. 1997 May;18(5):175-7. No abstract available.'}, {'pmid': '35316839', 'type': 'BACKGROUND', 'citation': 'Sims EK, Besser REJ, Dayan C, Geno Rasmussen C, Greenbaum C, Griffin KJ, Hagopian W, Knip M, Long AE, Martin F, Mathieu C, Rewers M, Steck AK, Wentworth JM, Rich SS, Kordonouri O, Ziegler AG, Herold KC; NIDDK Type 1 Diabetes TrialNet Study Group. Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective. Diabetes. 2022 Apr 1;71(4):610-623. doi: 10.2337/dbi20-0054.'}, {'pmid': '20668156', 'type': 'BACKGROUND', 'citation': 'Li R, Zhang P, Barker LE, Chowdhury FM, Zhang X. Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care. 2010 Aug;33(8):1872-94. doi: 10.2337/dc10-0843.'}, {'pmid': '7259754', 'type': 'BACKGROUND', 'citation': 'Chou WG, Pogell BM. Pamamycin inhibits nucleoside and inorganic phosphate transport in Staphylococcus aureus. Biochem Biophys Res Commun. 1981 May 15;100(1):344-50. doi: 10.1016/s0006-291x(81)80102-7. No abstract available.'}, {'pmid': '6290658', 'type': 'BACKGROUND', 'citation': 'Bonventre PF, Nickol AD, Ball EJ, Michael JG, Bubel HC. Development of protective immunity against bacterial and viral infections in tumor-bearing mice coincident with suppression of tumor immunity. J Reticuloendothel Soc. 1982 Jul;32(1):25-35.'}, {'pmid': '39662065', 'type': 'BACKGROUND', 'citation': 'Haller MJ, Bell KJ, Besser REJ, Casteels K, Couper JJ, Craig ME, Elding Larsson H, Jacobsen L, Lange K, Oron T, Sims EK, Speake C, Tosur M, Ulivi F, Ziegler AG, Wherrett DK, Marcovecchio ML. ISPAD Clinical Practice Consensus Guidelines 2024: Screening, Staging, and Strategies to Preserve Beta-Cell Function in Children and Adolescents with Type 1 Diabetes. Horm Res Paediatr. 2024;97(6):529-545. doi: 10.1159/000543035. Epub 2024 Dec 11.'}, {'pmid': '37931637', 'type': 'BACKGROUND', 'citation': 'Taylor PN, Collins KS, Lam A, Karpen SR, Greeno B, Walker F, Lozano A, Atabakhsh E, Ahmed ST, Marinac M, Latres E, Senior PA, Rigby M, Gottlieb PA, Dayan CM; Trial Outcome Markers Initiative collaboration. C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis. Lancet Diabetes Endocrinol. 2023 Dec;11(12):915-925. doi: 10.1016/S2213-8587(23)00267-X. Epub 2023 Nov 3.'}, {'pmid': '28772271', 'type': 'BACKGROUND', 'citation': 'Fonolleda M, Murillo M, Vazquez F, Bel J, Vives-Pi M. Remission Phase in Paediatric Type 1 Diabetes: New Understanding and Emerging Biomarkers. Horm Res Paediatr. 2017;88(5):307-315. doi: 10.1159/000479030. Epub 2017 Aug 3.'}, {'pmid': '7156298', 'type': 'BACKGROUND', 'citation': 'Boulenger JP, Uhde TW. Caffeine consumption and anxiety: preliminary results of a survey comparing patients with anxiety disorders and normal controls. Psychopharmacol Bull. 1982 Oct;18(4):53-7. No abstract available.'}, {'pmid': '33569058', 'type': 'BACKGROUND', 'citation': 'Gomez-Munoz L, Perna-Barrull D, Villalba A, Rodriguez-Fernandez S, Ampudia RM, Teniente-Serra A, Vazquez F, Murillo M, Perez J, Corripio R, Bel J, Vives-Pi M. NK Cell Subsets Changes in Partial Remission and Early Stages of Pediatric Type 1 Diabetes. Front Immunol. 2021 Jan 25;11:611522. doi: 10.3389/fimmu.2020.611522. eCollection 2020.'}, {'pmid': '32697399', 'type': 'BACKGROUND', 'citation': 'Vandamme C, Kinnunen T. B cell helper T cells and type 1 diabetes. Scand J Immunol. 2020 Oct;92(4):e12943. doi: 10.1111/sji.12943.'}, {'pmid': '9418549', 'type': 'BACKGROUND', 'citation': 'Larsen P. [Police always ready for a noncommitted talk. Interview by Anne Vesterdal]. Sygeplejersken. 1997 Oct 31;97(44):4-7. No abstract available. Danish.'}, {'pmid': '11246869', 'type': 'BACKGROUND', 'citation': "Bischof LJ, Martin CC, Svitek CA, Stadelmaier BT, Hornbuckle LA, Goldman JK, Oeser JK, Hutton JC, O'Brien RM. Characterization of the mouse islet-specific glucose-6-phosphatase catalytic subunit-related protein gene promoter by in situ footprinting: correlation with fusion gene expression in the islet-derived betaTC-3 and hamster insulinoma tumor cell lines. Diabetes. 2001 Mar;50(3):502-14. doi: 10.2337/diabetes.50.3.502."}, {'pmid': '39946833', 'type': 'BACKGROUND', 'citation': 'Luo S, Zhang L, Wei C, Guo C, Meng Z, Zeng H, Hou L, Wang L, Liu Z, Du Y, Tan S, Zhang Y, Xu X, Liang L, Zhou Y. TCL1A in naive B cells as a therapeutic target for type 1 diabetes. EBioMedicine. 2025 Mar;113:105593. doi: 10.1016/j.ebiom.2025.105593. Epub 2025 Feb 12.'}, {'pmid': '2805448', 'type': 'BACKGROUND', 'citation': 'Ueda M, Nomura G, Shibata H, Nishida H, Moriyama A, Kumagai E, Toshima H. Assessment of cardiopulmonary baroreflex function in hypertensive and normotensive subjects with or without hypertensive relatives. Clin Exp Pharmacol Physiol Suppl. 1989;15:89-92. doi: 10.1111/j.1440-1681.1989.tb03000.x.'}, {'pmid': '8065060', 'type': 'BACKGROUND', 'citation': 'Yamaoka K, Koizumi K, Asahina Y, Tajiri K, Sakai Y, Tazawa J, Akabane H, Marumo F, Sato C. [Hepatocellular carcinoma associated with autoimmune hepatitis--a case report and a review of the literatures]. Nihon Shokakibyo Gakkai Zasshi. 1994 Jul;91(7):1262-7. No abstract available. Japanese.'}, {'pmid': '10457110', 'type': 'BACKGROUND', 'citation': 'Fernandez J, Blanca M, Soriano V, Sanchez J, Juarez C. Epidemiological study of the prevalence of allergic reactions to Hymenoptera in a rural population in the Mediterranean area. Clin Exp Allergy. 1999 Aug;29(8):1069-74. doi: 10.1046/j.1365-2222.1999.00614.x.'}, {'pmid': '3253030', 'type': 'BACKGROUND', 'citation': 'Wilson SC, Oakey RE, Scott JS. In-vivo and in-vitro endocrine investigation of pure gonadal dysgenesis. Clin Endocrinol (Oxf). 1988 Nov;29(5):485-94. doi: 10.1111/j.1365-2265.1988.tb03697.x.'}, {'pmid': '3661605', 'type': 'BACKGROUND', 'citation': 'Long KJ. Abused statistical language in journal articles. Am J Med. 1987 Sep;83(3):607-8. doi: 10.1016/0002-9343(87)90793-5. No abstract available.'}, {'pmid': '10886892', 'type': 'BACKGROUND', 'citation': 'Scliar M. [Premarital examination: a rite of passage in Public Health]. Cad Saude Publica. 1997 Jul;13(3):527-530. doi: 10.1590/s0102-311x1997000300028. Portuguese.'}, {'pmid': '4622200', 'type': 'BACKGROUND', 'citation': 'Gingerich PD. The development of sexual dimorphism in the bony pelvis of the squirrel monkey. Anat Rec. 1972 Mar;172(3):589-95. doi: 10.1002/ar.1091720312. No abstract available.'}, {'pmid': '11766439', 'type': 'BACKGROUND', 'citation': 'Matthews PV, Newell LM. Disease management at a crossroads. Healthc Inform. 2001 Jul;18(7):38-41. No abstract available.'}, {'pmid': '11090024', 'type': 'BACKGROUND', 'citation': 'Shawa T, Cohen R, Jansen D, McKinnon W. Revisiting breast masses with the plastic surgeon: suggestions for biopsy and resection. Am Surg. 2000 Nov;66(11):1077-9.'}, {'pmid': '9870768', 'type': 'BACKGROUND', 'citation': 'Carter DH, Scully AJ, Davies RM, Aaron JE. Evidence for phosphoprotein microspheres in bone. Histochem J. 1998 Sep;30(9):677-86. doi: 10.1023/a:1003490506980.'}, {'pmid': '9827938', 'type': 'BACKGROUND', 'citation': 'Henon P, Sovalat H, Becker M, Arkam Y, Ojeda-Uribe M, Raidot JP, Husseini F, Wunder E, Bourderont D, Audhuy B. Primordial role of CD34+ 38- cells in early and late trilineage haemopoietic engraftment after autologous blood cell transplantation. Br J Haematol. 1998 Nov;103(2):568-81. doi: 10.1046/j.1365-2141.1998.01066.x.'}, {'pmid': '7228996', 'type': 'BACKGROUND', 'citation': 'Pontiroli AE, De Castro e Silva E, Mazzoleni F, Alberetto M, Baio G, Pellicciotta G, De Pasqua A, Stella L, Girardi AM, Pozza G. The effect of histamine and H1 and H2 receptors on prolactin and luteinizing hormone release in humans: sex differences and the role of stress. J Clin Endocrinol Metab. 1981 May;52(5):924-8. doi: 10.1210/jcem-52-5-924.'}, {'pmid': '5491594', 'type': 'BACKGROUND', 'citation': 'Demant F, Gubas J, Predmersky M, Vereb J. [Takayasu syndrome in a 13-year-old girl]. Bratisl Lek Listy. 1970 Dec;54(6):675-81. No abstract available. Slovak.'}, {'pmid': '3781470', 'type': 'BACKGROUND', 'citation': 'Suzuki H. [Heme transport from mitochondria to apocytochrome b5 incorporated into phospholipid vesicles by cytosolic liver protein]. Hokkaido Igaku Zasshi. 1986 Sep;61(5):800-6. Japanese.'}, {'pmid': '11424550', 'type': 'BACKGROUND', 'citation': 'Fitch CW, Neville J. Nutrient intake of infants hospitalized with lower respiratory tract infections. J Am Diet Assoc. 2001 Jun;101(6):690-2. doi: 10.1016/S0002-8223(01)00173-0. No abstract available.'}, {'pmid': '10758755', 'type': 'BACKGROUND', 'citation': 'Sporisevic L, Hasanbegovic E, Hadzihasanovic E, Bajraktarevic A, Khatib H, Hamamdzic M. [Advantages and disadvantages in the use of central venous catheters in children with malignant diseases]. Med Arh. 1999;53(3 Suppl 2):19-22. Croatian.'}, {'pmid': '11076468', 'type': 'BACKGROUND', 'citation': 'Nyman U. [Disastrous situation when it comes to vascular intervention! State-of-the-art endovascular treatment--if the radiology will manage to realize it]. Lakartidningen. 2000 Sep 27;97(39):4284-6. No abstract available. Swedish.'}, {'pmid': '9750947', 'type': 'BACKGROUND', 'citation': 'Mallin K. A nested case-control study of bladder cancer incidence in a steel manufacturing plant. Am J Ind Med. 1998 Oct;34(4):393-8. doi: 10.1002/(sici)1097-0274(199810)34:43.0.co;2-y.'}, {'pmid': '10998887', 'type': 'BACKGROUND', 'citation': 'Suzuki H, Fukuda H, Hirabayashi Y, Saitoh K, Igarashi T, Shimizu R. [Anesthetic management of a patient with May-Hegglin anomaly]. Masui. 2000 Aug;49(8):899-900. Japanese.'}, {'type': 'BACKGROUND', 'citation': 'Echeverri AF, Tobón GJ. Autoimmune diabetes mellitus (Type 1A) In: Anaya JM, Shoenfeld Y, Rojas-Villarraga A, et al., editors. Autoimmunity: From Bench to Bedside [Internet]. Bogota (Colombia): El Rosario University Press; 2013 Jul 18. Chapter 29. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459476/'}, {'pmid': '38169963', 'type': 'BACKGROUND', 'citation': 'Jia X, Yu L. Understanding Islet Autoantibodies in Prediction of Type 1 Diabetes. J Endocr Soc. 2024 Jan 2;8(1):bvad160. doi: 10.1210/jendso/bvad160. eCollection 2023 Dec 1.'}, {'pmid': '16306341', 'type': 'BACKGROUND', 'citation': 'Pihoker C, Gilliam LK, Hampe CS, Lernmark A. Autoantibodies in diabetes. Diabetes. 2005 Dec;54 Suppl 2:S52-61. doi: 10.2337/diabetes.54.suppl_2.s52.'}, {'pmid': '32139386', 'type': 'BACKGROUND', 'citation': 'Makimattila S, Harjutsalo V, Forsblom C, Groop PH; FinnDiane Study Group. Every Fifth Individual With Type 1 Diabetes Suffers From an Additional Autoimmune Disease: A Finnish Nationwide Study. Diabetes Care. 2020 May;43(5):1041-1047. doi: 10.2337/dc19-2429. Epub 2020 Mar 5.'}, {'pmid': '33293704', 'type': 'BACKGROUND', 'citation': 'Roep BO, Thomaidou S, van Tienhoven R, Zaldumbide A. Type 1 diabetes mellitus as a disease of the beta-cell (do not blame the immune system?). Nat Rev Endocrinol. 2021 Mar;17(3):150-161. doi: 10.1038/s41574-020-00443-4. Epub 2020 Dec 8.'}, {'pmid': '10864267', 'type': 'BACKGROUND', 'citation': 'Dubey JP, Speer CA, Bowman DD, Horton KM, Venturini C, Venturini L. Experimental transmission of Sarcocystis speeri Dubey and Lindsay, 1999 from the South American opossum (Didelphis albiventris) to the North American opossum (Didelphis virginiana). J Parasitol. 2000 Jun;86(3):624-7. doi: 10.1645/0022-3395(2000)086[0624:ETOSSD]2.0.CO;2.'}, {'pmid': '36983604', 'type': 'BACKGROUND', 'citation': 'Popoviciu MS, Kaka N, Sethi Y, Patel N, Chopra H, Cavalu S. Type 1 Diabetes Mellitus and Autoimmune Diseases: A Critical Review of the Association and the Application of Personalized Medicine. J Pers Med. 2023 Feb 26;13(3):422. doi: 10.3390/jpm13030422.'}, {'pmid': '10056161', 'type': 'BACKGROUND', 'citation': 'Fokas AS, Liu QM. Nonlinear interaction of traveling waves of nonintegrable equations. Phys Rev Lett. 1994 May 23;72(21):3293-3296. doi: 10.1103/PhysRevLett.72.3293. No abstract available.'}], 'seeAlsoLinks': [{'url': 'https://idiapjgol.org/es/', 'label': 'Related Info'}]}, 'descriptionModule': {'briefSummary': "This study aims to identify early-stage type 1 diabetes (T1D) in children aged 2-6 and 8-10 years through autoantibody (Ab) screening, genetic and immunological analyses, and to evaluate the effectiveness of educational interventions, as well as the feasibility and acceptability of their implementation.\n\nIt is a prospective cohort study involving 2,169 children attending primary healthcare centres in the Barcelonès area. Eligible participants will be those engaged in routine paediatric preventive programe with parental informed consent. The screening process consists of three visits: Visit 1: Capillary blood collection for 3 T1D related Ab (3-screen ELISA). Visit 2: Confirmation of positive results through a new venous blood sample to determine single T1D related Ab and metabolic tests (fasting glucose, HbA1c, C-peptide), HLA, imme cell study. Visit 3: Risk stratification based on Ab presence: Group A (negative), Group B (one positive Ab, at risk of T1D), and Group C (two positive Ab, diagnosed at stage 1 or 2). Immunological and metabolic changes will be monitored, and screening effectiveness will be assessed in terms of sensitivity, specificity, and false positive/negative rates. The association between HLA genotype and Ab positivity will be analysed using logistic regression. A cost-effectiveness analysis will be conducted alongside a qualitative evaluation of parents' and stakeholders' perceptions regarding the screening process.This study will provide evidence to optimise early T1D detection and its implementation in primary care.", 'detailedDescription': 'Detailed Description 12000 characters. :\n\nType 1 Diabetes Mellitus (T1D) is a chronic autoimmune disease characterized by the destruction of insulin-producing beta cells in the pancreas. The exact cause is not fully understood, involving a combination of genetic predisposition and environmental triggers. Common symptoms include frequent urination, increased thirst, hunger, weight loss, blurred vision, fatigue, and slow wound healing. Currently, there is no known method to prevent T1D, insulin therapy is essential for survival, often administered via injections or insulin pumps. Lifestyle modifications, such as diet and exercise, are also crucial for management. Untreated or poorly managed T1D can lead to serious complications, including diabetic ketoacidosis (DKA), heart disease, kidney failure, and vision problems. Autoantibodies (Ab) play a crucial role in the development and diagnosis of T1D. Ab target various islet cell antigens and are strongly associated with the autoimmune pathogenesis of β-cell destruction. The main Ab related to T1D includes 1. Insulin Ab (IAA), 2. Glutamic acid decarboxylase Ab (GADA), 3. Protein tyrosine phosphatase-like IA-2 Ab (IA-2A), 4. Zinc transporter Antibodies (ZnT8A)6,7. These Abs can appear years before symptoms manifest, indicating an ongoing autoimmune process. The presence of multiple Ab significantly increases the risk of developing T1D. Individuals with two or more positive Ab have a 68% 5-year risk, while those with three Ab have an estimated 100% 5-year risk.\n\nAb testing is used to distinguish between autoimmune T1D and other forms of diabetes, to identify individuals at risk of developing T1D, or to stage the progression of T1D. A General Hypothesis of this study is that the diagnosis of early-stage Type 1 diabetes (T1D) in children through targeted screening leads to significant clinical benefits by enabling timely intervention to prevent complications, and improved metabolic and psychosocial outcomes.\n\nThe specific Hypotheses are:\n\n1. Children at risk of developing T1D can be identified by detecting anti-GAD (GADA), anti-IA2(IA-2A), anti-zinc transporter 8 (ZnT8A), and anti insulin (IAA) antibodies.\n2. The presence and levels of these antibodies vary by sex and age, reflecting differences in susceptibility and disease progression.\n3. Immune cell populations relevant to immune regulation show distinct patterns in two age groups of children at risk of Type 1 diabetes. These patterns vary by sex and age, indicating early immunological changes associated with early stages of diabetes.\n4. Certain HLA genotypes are significantly associated with predisposition to develop T1D, influencing disease onset and progression\n5. Educational interventions and staging, followed by enrolment in a monitoring protocol, increase disease awareness, improve self-management skills, and enhance psychosocial well-being in children with early-stage T1D and their parents\n6. Screening for early-stage T1D in children is feasible and acceptable among parents, as evidenced by positive feedback on the screening process, educational materials, and overall experience.\n7. The implementation of the T1D Watch Study for early detection of T1D through systematic screening is a cost-effective strategy compared to standard clinical diagnosis.\n\nThis study aims to identify pre-clinical and clinical stages of T1D in two age groups, young children (from two to six years) and older children (from seven to ten years), and assess the proportion of confirmed cases receiving timely interventions to prevent complications. The specific objectives are:\n\n1. To identify children at risk of developing type 1 diabetes by screening GADA,IA-2A,ZnT8A and IAA associated with increased susceptibility by sex and age.\n2. To analyze cell populations relevant to immune regulation to understand early immunological changes in pre diabetes by sex, and two age groups.\n3. To analyze the presence of HLA haplotypes of susceptibility to T1D and relate it to other variables (number and titer of antibodies, age of onset ,and clinical results).\n4. Evaluate the improvement of the disease awareness, self-management skills, and psychosocial well-being of children (and their parents) who follow educational interventions and enrolment in a monitoring protocol of early-stage Type 1 diabetes.\n5. Evaluate the feasibility and acceptability of screening by feedback questionnaires.\n6. Analyze the cost-effectiveness of the screening T1D Watch Study\n\nThis is a clinical-epidemiological population-based study aimed at identifying preclinical and evaluating the proportion of confirmed cases receiving timely interventions to prevent acute complications at diagnosis. In addition, this study was designed as a prospective cohort that will longitudinally assess immunological and metabolic changes in children at risk of T1D and evaluate the feasibility, acceptability, and educational impact of implementing a population-based screening programme.\n\nThe study population consists of 2200 children (boys and girls) aged 2-10 years from three municipalities of Barcelona, Spain. Participants will be recruited from 14 primary care centers (CAPs) in three municipalities in Catalonia, Spain: Badalona Santa Coloma de Gramenet and El Masnou. Follow-up visit to pre-diabetic outcomes will take place at the University Hospital Germans Trias i Pujol. Recruitment and enrolment will be conducted by pediatricians and nurses (HCWs) in Primary Health Centers (PHCs). HCWs will provide written information to the participants who meet the inclusion criteria, and if they are willing to participate, they will be enrolled by signing the informed consent. After this, screening will be conducted on a capillary blood sample (Ab 3-screen ELISA). All the participants enrolled in the study will be called for a visit (visit 1). Only those with a positive result in the Ab 3-screen ELISA, will be called for a second visit and subsequent ones. When the result is negative, it will be recorded in the child\'s medical history and communicated via health personal app (La Meva Salut). The recruitment period is from 1/5/26 to 31/12/2027 and the Study Period from 1/1/26 to 31/12/2028.\n\nVisit 1 consists of collecting socio-ethnic demographic and clinical data from all participants. Besides, HCWs of PHCs will collect capillary blood using a lancet (250 μL). The test measures three diabetes-related autoantibodies (GADA, IA-2A, ZnT8A) using a validated ELISA method with 95.33% sensitivity and 97.42% specificity46. In 100 participants, both capillary and venous blood will be tested for accuracy. A result ≥20 IU is considered positive and will be communicated to the pediatrician via encrypted email to advise the child to visit 2 Parents will receive results via SMS, and at their next visit, with results also recorded in electronic health records (EHR). Blood samples will be sent to the LCMN. The negative result is recorded in the child\'s medical history and communicated via La Meva Salut app, ending the child\'s participation in the T1D WATCH study. If a positive result, the child will be scheduled for a confirmation Visit2. In the follow-up, a new blood sample will be collected to determine the single Ab, and the metabolic test (Basal glucose, HbA1c, C-peptide).Up to 5 mL of blood will be collected, and an additional 4 mL (EDTA sample). Samples will be sent to LCMN within 4 hours, processed, and stored properly. If the initial test is positive (≥20 IU), parents are informed by phone, and the child is invited for Visit 2 to provide a venous blood sample. This sample undergoes further testing, including single ELISA assays for autoantibodies (Ab) (GADA, IA-2A, ZnT8A, and IAA) and confirmation by RBA assay. Additional tests include HLA genotyping and lymphocyte analysis. The diagnosis will be recorded in the child\'s EHR using the ICD-10 codes for elevated blood glucose and pre-diabetes\n\nVisit 3 aims to stratify early-stage T1D patients. After visit 2, participants will be classified into 3 groups:\n\n* Group A: No Ab. Negative screening test. This result will be recorded in the child\'s medical history and communicated via the la Meva Salut app, ending the child\'s participation in the T1D WATCH study.\n* Group B (at-risk T1D): Only one positive Ab. Parents of children with a single positive Ab will be contacted at PHCs, offered specific diabetes education, and will receive regular visits with varying frequency depending on age. Under 3 years, every 6 months, and over 3 years, every 12 months. The visit of follow-up includes the monitoring of single antibodies tests, HbA1c, C-peptide, and Glucose\n* Group C (Stage 1, 2 T1D): Two positive Ab. The child is diagnosed following ADA and ISPAD guidelines.\n\nConsidering the total population of 40.000 children aged from 2 to 10 years in the participating municipalities, an expected antibody prevalence of 2%, ± 0,58% and a 95% confidence level, the required sample size is 2169 individuals. Similar precision could be used around sensibility 95% and Specificity 98%.\n\nElectronic data capture using a specific REDCap for the study. To protect the privacy of our participants, we used cryptography hashtags to anonymize the project database. We also employed the same 10-digit numeric encoding system hosted by REDCap, version 12.4.22 --Vanderbilt University, for the T1D WATCH study.\n\nThe T1D WATCH study will generate critical data on the prevalence of pre-symptomatic T1D in Spain, autoantibody patterns, and their correlation with genetic and metabolic markers. The expected contributions include:\n\n1. Improved risk stratification and predictive models for T1D development.\n2. Insights into immunological changes during the early stage T1D phase.\n3. Assessment of the psychosocial impact of screening and early diagnosis.\n4. Evidence supporting future immuno-prevention trials aimed at delaying or preventing T1D onset.\n5. Evaluation of the feasibility of integrating screening into routine primary care through the "Programa Creixer amb Salut".\n\nThis study evaluates the feasibility and impact of integrating T1D screening into routine pediatric care, focusing on the number of cases diagnosed and its effect on disease control. Rather than being a Type 2 implementation study, which typically assesses strategies to enhance the adoption of evidence-based interventions, this project primarily investigates the clinical and public health implications of early screening. The study will monitor the effectiveness of autoantibody screening in identifying at-risk children and facilitating timely referrals within standard clinical pathways. Newly diagnosed children will be referred to standard clinical pathways for management'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD'], 'maximumAge': '10 Years', 'minimumAge': '2 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'The study population consists of children (boys and girls) aged 2-10 years from the three municipalities of Barcelona, spain.', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Age corresponding to one of the predefined screening groups:\n\n * Young children: 2-6 years\n * Older children: 7-10 years\n* Attendance at routine pediatric visits within the Preventive Activities and Health Promotion Programme in Childhood in Catalonia ("Creixer amb Salut") at the specified ages (2-10 years)\n* Written informed consent provided by parents or legal guardians\n\nExclusion Criteria:\n\n* Presence of primary immunodeficiency\n* Current treatment with immunosuppressive therapy\n* Ongoing participation in another clinical trial\n* Refusal to participate or inability to comply with study procedures'}, 'identificationModule': {'nctId': 'NCT07492550', 'acronym': 'T1DWATCH', 'briefTitle': 'The T1DWATCH Study: a Screening for Type 1 Diabetes Autoantibodies in Children for Early Detection and Intervention.', 'organization': {'class': 'OTHER', 'fullName': "Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina"}, 'officialTitle': 'T1D WATCH Study, a Comprehensive Screening for Type 1 Diabetes Autoantibodies in Children: A Proactive Approach to Early Detection and Intervention', 'orgStudyIdInfo': {'id': 'T1D_Watch'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Grup A', 'description': 'No Ab. Negative screening test.'}, {'label': 'Grup B - at risk T1D', 'description': 'Only one positive Ab.'}, {'label': 'Grup C - Stage 1, 2 T1D', 'description': 'Two positive Ab'}]}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Concepción V Fors, PhD', 'role': 'CONTACT', 'email': 'cviolanf.mn.ics@gencat.cat', 'phone': '+34 607 07 25 92'}, {'name': 'Fabiana G dos Santos, PhD', 'role': 'CONTACT', 'email': 'fganem@idiapjgol.org', 'phone': '+34679080950'}], 'overallOfficials': [{'name': 'Bibiana S Quirant, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Germans Trias i Pujol Research Institute | IGTP'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO', 'description': 'Only anonymized data can be shared in this study.'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Fabiana Sherine Ganem dos Santos', 'class': 'OTHER'}, 'collaborators': [{'name': 'Germans Trias i Pujol Research Institute | IGTP', 'class': 'UNKNOWN'}, {'name': 'Institut de Recerca Germans Trias i Pujol', 'class': 'UNKNOWN'}], 'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorTitle': 'Co-Investigator', 'investigatorFullName': 'Fabiana Sherine Ganem dos Santos', 'investigatorAffiliation': "Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina"}}}}